ERBB2 and breast carcinoma: We also show that elevated expression of HER3 in HER2-over-expressing breast cancer cells results in resistance to hormone therapy (tamoxifen), HER2-targeted therapy (trastuzumab and lapatinib) and chemotherapy (paclitaxel) [67–71].